NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free NERV Stock Alerts $2.44 +0.01 (+0.41%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.43▼$2.4950-Day Range$2.42▼$8.8052-Week Range$2.29▼$13.49Volume4,157 shsAverage Volume99,925 shsMarket Capitalization$17.03 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Minerva Neurosciences alerts: Email Address Minerva Neurosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside351.5% Upside$11.00 Price TargetShort InterestHealthy0.56% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.24Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.57) to ($4.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.61 out of 5 starsMedical Sector263rd out of 908 stocksPharmaceutical Preparations Industry110th out of 423 stocks 3.0 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.56% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 24.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.89. Previous Next 1.8 News and Social Media Coverage News SentimentMinerva Neurosciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 34.56% of the stock of Minerva Neurosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to decrease in the coming year, from ($3.57) to ($4.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Minerva Neurosciences Stock (NASDAQ:NERV)Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Read More NERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NERV Stock News HeadlinesApril 20, 2024 | msn.comPolice: 3 injured in Minerva Park single-vehicle crashApril 20, 2024 | msn.comOff-duty firefighters & neighbor rescue baby, residents from burning Minerva houseApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 20, 2024 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average of $5.57April 4, 2024 | msn.comPrairie voles display signs of human-like depression, show promise as animal modelMarch 31, 2024 | msn.comNew track and field season gives Minerva sprinter Kyleigh Lippincott a fresh startMarch 14, 2024 | msn.comPotts Point homelessness encampment moved on from Minerva-Metro Theatre siteMarch 14, 2024 | tmcnet.comMinerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 RankingsApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 13, 2024 | msn.comRenovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open houseMarch 13, 2024 | tmcnet.comMinerva Named Top AI & Data Product in the 2024 Product AwardsFebruary 27, 2024 | markets.businessinsider.comHold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial ConstraintsFebruary 27, 2024 | finance.yahoo.comMinerva schizophrenia drug rejected by FDAFebruary 27, 2024 | marketwatch.comFDA Turns Away Minerva's Roluperidone Schizophrenia DrugFebruary 27, 2024 | morningstar.comMinerva Neurosciences Shares Slide on Latest FDA Roluperidone SetbackFebruary 27, 2024 | msn.comRegulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More DataFebruary 27, 2024 | msn.comMinerva falls as FDA rejects schizophrenia therapyFebruary 27, 2024 | bizjournals.comFDA rejects Burlington biotech’s schizophrenia drug, sends stock tumblingFebruary 27, 2024 | reuters.comUS FDA declines to approve Minerva Neurosciences' schizophrenia drugFebruary 27, 2024 | finance.yahoo.comMinerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaFebruary 25, 2024 | msn.comREUTERS NEWS SCHEDULE AT 7:00 a.m. SGT /6:00 p.m. ETFebruary 22, 2024 | benzinga.com2NERV : Minerva Neurosciences: Q4 Earnings InsightsFebruary 22, 2024 | sfgate.comMinerva Neurosciences: Q4 Earnings SnapshotFebruary 22, 2024 | finance.yahoo.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesFebruary 22, 2024 | globenewswire.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesFebruary 9, 2024 | seekingalpha.comSUNW, NSTG and NERV among mid-day moversFebruary 7, 2024 | msn.comMarket Street Art Spot expands gallery and marks 13th anniversary in MinervaSee More Headlines Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+351.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,000,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-50.27% Debt Debt-to-Equity RatioN/A Current Ratio12.57 Quick Ratio12.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.07) per share Price / Book-0.60Miscellaneous Outstanding Shares6,990,000Free Float6,545,000Market Cap$17.03 million OptionableNot Optionable Beta0.21 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Remy Luthringer Ph.D. (Age 63)Executive Chairman & CEO Comp: $853.58kMr. Geoffrey Robin Race F.C.M.A. (Age 63)M.B.A., President Comp: $628.46kMr. Frederick W. Ahlholm CPA (Age 58)Senior VP, CFO & Secretary Comp: $567.49kMr. Joseph Reilly (Age 49)Senior VP & COO Comp: $461kMr. William B. Boni (Age 72)Vice President of Investor Relations & Corporate Communications Prof. Michael Davidson M.D. (Age 74)Chief Medical Officer Comp: $657.47kMore ExecutivesKey CompetitorsBenitec BiopharmaNASDAQ:BNTCOrgenesisNASDAQ:ORGSVBI VaccinesNASDAQ:VBIVFSD PharmaNASDAQ:HUGEKALA BIONASDAQ:KALAView All CompetitorsInsidersRemy LuthringerSold 23,753 sharesTotal: $91,449.05 ($3.85/share)Geoff RaceSold 22,082 sharesTotal: $85,015.70 ($3.85/share)Frederick W AhlholmSold 3,580 sharesTotal: $16,038.40 ($4.48/share)View All Insider Transactions NERV Stock Analysis - Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks. What is Minerva Neurosciences' stock price target for 2024? 1 equities research analysts have issued 1 year target prices for Minerva Neurosciences' stock. Their NERV share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 351.5% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts. How have NERV shares performed in 2024? Minerva Neurosciences' stock was trading at $6.15 at the beginning of the year. Since then, NERV stock has decreased by 60.4% and is now trading at $2.4365. View the best growth stocks for 2024 here. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 30,500 shares, a drop of 24.3% from the March 31st total of 40,300 shares. Based on an average trading volume of 115,900 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the company are short sold. View Minerva Neurosciences' Short Interest. When is Minerva Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NERV earnings forecast. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by $0.31. When did Minerva Neurosciences' stock split? Shares of Minerva Neurosciences reverse split before market open on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NERV) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
